

# OSENI - (12.5mg;15/30/45mg,25mg;15/30/45mg, Tablet)

Generic Name	ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE	Innovator	Takeda
Dosage	12.5mg;15/30/45mg,25mg;15/30/45mg, Tablet	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both alogliptin and pioglitazone is appropriate		
Complexities	Yes		

## **Chronology Of Events**

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

#### **Executive Summary**

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

#### **Patent Status**

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

### Launch Timelines and Competition

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

## **Chronology Of Events**

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.